Revance Therapeutics Inc

General ticker "RVNC" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $368.0M

Revance Therapeutics Inc does not follow the US Stock Market performance with the rate: -0.6%.

Estimated limits based on current volatility of 0.4%: low 3.62$, high 3.65$

Factors to consider:

  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [5.50$, 15.46$]
  • 2024-12-30 to 2025-12-30 estimated range: [4.77$, 13.26$]

Financial Metrics affecting the RVNC estimates:

  • Negative: Non-GAAP EPS, $ of -2.90 <= 0
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -25.15 <= 1.33
  • Negative: negative Net income

Similar symbols

Short-term RVNC quotes

Long-term RVNC plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $77.80MM $132.56MM $234.04MM
Operating Expenses $352.47MM $474.52MM $550.82MM
Operating Income $-274.68MM $-341.96MM $-316.78MM
Non-Operating Income $-6.63MM $-13.76MM $-6.91MM
Interest Expense $6.27MM $16.47MM $19.36MM
R&D Expense $116.25MM $101.29MM $79.41MM
Income(Loss) $-281.31MM $-355.72MM $-323.69MM
Taxes $0.00MM $0.70MM $0.30MM
Profit(Loss)* $-286.82MM $-356.42MM $-323.99MM
Stockholders Equity $68.47MM $12.60MM $-151.60MM
Inventory $10.15MM $18.32MM $45.58MM
Assets $531.16MM $581.90MM $478.45MM
Operating Cash Flow $-221.54MM $-193.55MM $-216.57MM
Capital expenditure $18.07MM $23.01MM $6.89MM
Investing Cash Flow $-29.66MM $-138.80MM $109.74MM
Financing Cash Flow $29.87MM $331.69MM $136.57MM
Earnings Per Share** $-4.25 $-4.90 $-3.83

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.